Takeda Announces New Assignments of Directors

Takeda Announces New Assignments of Directors

June 28, 2023

OSAKA, Japan, June 28, 2023 – Takeda (TSE:4502/NYSE:TAK) has announced new assignments of Directors, determined at the Board of Directors meeting, following the 147th Ordinary Meeting of Shareholders, held in Osaka today.

Takeda's Board of Directors has 12 members serving as External Directors out of a total of 15 members, helping to ensure transparency and objectivity. External Director Masami Iijima will continue to chair the Board of Directors. The Audit Committee, the Nominating Committee and the Compensation Committee will be composed solely of External Directors including their chairs.

Takeda highly values strong, independent governance and its Board of Directors helps to ensure that all decisions and actions are in the best interests of global stakeholders and aligned with the company’s values. This robust corporate governance model has been, and will continue to be, critical to Takeda's success.

Details of the new assignments are as follows:

1. New Assignment of Directors Who Are Not Audit and Supervisory Committee Members (Effective June 28, 2023)

Christophe WeberInternalExistingRepresentative Director, President & Chief Executive Officer
Andrew PlumpInternalExistingDirector, President, Research & Development
Constantine SaroukosInternalExistingDirector, Chief Financial Officer
Masami IijimaExternalExistingExternal Director, Chair of the Board Meeting
Olivier BohuonExternalExistingExternal Director
Jean-Luc ButelExternalExistingExternal Director
Ian ClarkExternalExistingExternal Director
Steven GillisExternalExistingExternal Director
John MaraganoreExternalExistingExternal Director
Michel OrsingerExternalExistingExternal Director
Miki TsusakaExternalNewExternal Director

2. Directors Who Are Audit and Supervisory Committee Members

Koji HatsukawaExternal Director, Head of Audit and Supervisory Committee
Yoshiaki FujimoriExternal Director, Audit and Supervisory Committee Member
Emiko HigashiExternal Director, Audit and Supervisory Committee Member
Kimberly A. ReedExternal Director, Audit and Supervisory Committee Member

Directors who are Audit and Supervisory Committee Members are within their 2-year tenure and were not subjects for reelection this year.

3. New Assignment of Nomination Committee and Compensation Committee Members (Effective June 28, 2023)

Nomination committee:

Masami Iijima (Chairperson), Jean-Luc Butel, Steven Gillis, Michel Orsinger, and Yoshiaki Fujimori (Observer: Christophe Weber)

Compensation committee:

Emiko Higashi (Chairperson), Olivier Bohuon, Ian Clark, and Michel Orsinger

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

Media Contacts:

Japanese Media

Jun Saito [email protected]

U.S. and International Media

Megan Ostrower [email protected] +1 772-559-4924

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.govGo to http://www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.